These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons. López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501 [TBL] [Abstract][Full Text] [Related]
4. Wauters F; Cornelissen T; Imberechts D; Martin S; Koentjoro B; Sue C; Vangheluwe P; Vandenberghe W Autophagy; 2020 Feb; 16(2):203-222. PubMed ID: 30945962 [TBL] [Abstract][Full Text] [Related]
5. Generation of an induced pluripotent stem cell line (GIBHi003-A) from a Parkinson's disease patient with mutant PINK1 (p. I368N). Abdul MM; Ibañez DP; Zhao P; Liu H; Zhong X; Li Y; Zhang M; Li W; Li Y; Ward C; Chen S; Wang D; Qin B; Esteban MA; Wang X; Fan W; Luo Z Stem Cell Res; 2019 Dec; 41():101607. PubMed ID: 31778937 [TBL] [Abstract][Full Text] [Related]
7. Phenotypical Differences in Neuronal Cultures Derived via Reprogramming the Fibroblasts from Patients Carrying Mutations in Parkinsonian Genes LRRK2 and PARK2. Konovalova EV; Novosadova EV; Grivennikov IA; Illarioshkin SN Bull Exp Biol Med; 2015 Oct; 159(6):772-5. PubMed ID: 26519280 [TBL] [Abstract][Full Text] [Related]
8. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition. Smith GA; Jansson J; Rocha EM; Osborn T; Hallett PJ; Isacson O Mol Neurobiol; 2016 Oct; 53(8):5161-77. PubMed ID: 26399642 [TBL] [Abstract][Full Text] [Related]
9. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998 [TBL] [Abstract][Full Text] [Related]
10. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis. Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355 [TBL] [Abstract][Full Text] [Related]
11. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease. Yonova-Doing E; Atadzhanov M; Quadri M; Kelly P; Shawa N; Musonda ST; Simons EJ; Breedveld GJ; Oostra BA; Bonifati V Parkinsonism Relat Disord; 2012 Jun; 18(5):567-71. PubMed ID: 22445250 [TBL] [Abstract][Full Text] [Related]
12. I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway. Ohta E; Nihira T; Uchino A; Imaizumi Y; Okada Y; Akamatsu W; Takahashi K; Hayakawa H; Nagai M; Ohyama M; Ryo M; Ogino M; Murayama S; Takashima A; Nishiyama K; Mizuno Y; Mochizuki H; Obata F; Okano H Hum Mol Genet; 2015 Sep; 24(17):4879-900. PubMed ID: 26056228 [TBL] [Abstract][Full Text] [Related]
13. Generation of an induced pluripotent stem cell line (CSC-41) from a Parkinson's disease patient carrying a p.G2019S mutation in the LRRK2 gene. Marote A; Pomeshchik Y; Collin A; Goldwurm S; Lamas NJ; Pinto L; Salgado AJ; Roybon L Stem Cell Res; 2018 Apr; 28():44-47. PubMed ID: 29414418 [TBL] [Abstract][Full Text] [Related]
14. A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease. Nishioka K; Kefi M; Jasinska-Myga B; Wider C; Vilariño-Güell C; Ross OA; Heckman MG; Middleton LT; Ishihara-Paul L; Gibson RA; Amouri R; Ben Yahmed S; Ben Sassi S; Zouari M; El Euch G; Farrer MJ; Hentati F J Neurol Neurosurg Psychiatry; 2010 Apr; 81(4):391-5. PubMed ID: 19726410 [TBL] [Abstract][Full Text] [Related]
15. Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient-derived induced pluripotent stem cells. Son MY; Sim H; Son YS; Jung KB; Lee MO; Oh JH; Chung SK; Jung CR; Kim J Neuropathol Appl Neurobiol; 2017 Dec; 43(7):584-603. PubMed ID: 28235153 [TBL] [Abstract][Full Text] [Related]
16. Generation of a human iPSC line (CIBi014-A) from a patient with Parkinson's disease carrying a novel heterozygotic PARK8 (LRRK2) mutation. Li L; Si X; Yang J; Lei M; Liu H; Ruan J; Fu H; Li W; Yang H; Lei X; Sang H Stem Cell Res; 2023 Feb; 66():102995. PubMed ID: 36528012 [TBL] [Abstract][Full Text] [Related]